Effects of immunosuppressive drugs on platelet aggregation and soluble P-selectin levels in renal transplant patients

Renal Failure

Volumn 31, Issue 2, 2009, Pages 111-117

  Sahin, Garip ^a   Akay, Olga Meltem ^a   Kus, Esin ^a   Bal, Cengiz ^a   Yalcin, Ahmet Ugur ^a   Gulbas, Zafer ^a  

^a OSMANGAZI UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

Cyclosporine; Platelet aggregation; Renal transplantation; Soluble P selectin; Tacrolimus

Indexed keywords

ADENOSINE DIPHOSPHATE; ADRENALIN; COLLAGEN; CYCLOSPORIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PADGEM PROTEIN; RISTOCETIN; TACROLIMUS;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

ADULT; BIOLOGICAL MARKERS; CYCLOSPORINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; P-SELECTIN; PLATELET AGGREGATION; TACROLIMUS; YOUNG ADULT;

EID: 61649092842     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220802599163     Document Type: Article

References (21)

1. Pham PT, Pham PC, Danovitch GM. Cardiovascular disease posttransplant. Semin Nephrol. 2007; 27(4):430-444.
2. Sato K, Ogawa K, Onumata O, et al. Cause of death in renal transplant patients: A comparison between azathioprine and ciclosporin. Surg Today. 2001;31:681-687.
3. Aker S, Ivens K, Grabensee B, Heering P. Cardiovascular risk factors and diseases after renal transplantation. Int Urol Nephrol. 1998;30(4):777-788.
4. Briggs JD. Causes of death after renal transplantation. Nephrol Dial Transplant. 2001;16:1545-1549.
5. Ross R. The pathogenesis of atherosclerosis: An update. N Engl J Med. 1986;314:488-500.
6. Vanrenterghem Y, Roels L, Lerut T, et al. Tromboembolic complications and haemostatic changes in cyclosporine-treated cadaveric kidney allograft recipients. Lancet. 1985;1:999-1002.
7. Grace AA, Barradas MA, Mikhailidis DP, Jeremy JY, Sweny P, Dandona P. Cyclosporine A enhaces platelet aggregation. Kidney Int. 1987;32(6):889-895.
8. Malyszko J, Malyszko JS, Takada A, Mysliwiec M. Effects of immunosuppressive drugs platelet aggregation in vivo. Ann Transplant. 2002;7(1):55-68.
9. Graff J, Klinkhardt U, Harder S, et al. Immunosuppressive therapy regimen and platelet activation in renal transplant patients. Clin Pharmacol Ther. 2002;72(4):411-418.
10. Malyszko J, Malyszko JS, Pawlak K, Michal M. The coagulo-lytic system and endothelial function in cyclosporine-treated kidney allograft recipients. Transplantation. 1996;62(2):828-830.
11. Verpooten GA, Cools FJ, Van der Planken MG, et al. Elevated plasminogen activator inhibitor levels in cyclosporine-treated renal allograft recipients. Nephrol Dial Transplant. 1996;11:347-351.
12. Opelz G, Wujciak T, Ritz E, et al. Association of chronic kidney graft failure with recipient blood pressure. Kidney Int. 1998;53:217-222.
13. Canzanello VJ, Schwartz L, Tater SJ, et al. Evolution of cardiovascular risk after liver transplantation: A comparison of cyclosporine A and tacrolimus FK(506). Liver Transpl Surg. 1997;3:1-9.
14. Grace AA, Barradas MA, Mikhailidis DP, et al. Cyclosporine A enhances platelet aggregation. Kidney Int. 1987;32(6):889-895.
15. Fernandes JB, Naik UP, Markell MS, Kornecki E. Comparative investigation of the effects of the immunusuppresants cyclosporine A, cyclosporine G, and FK-506 on platelet aggregation. Cell Mol Biol Res. 1993;39(3):265-274.
16. Klein BC, Bach D, Rehfeld I, et al. Influence of mycophenolic acid and FK-506 on human platelet activation in vitro. Kidney Blood Press Res. 2000;23(2):119-124.
17. Blann AD, Lip GY. Hypothesis: Is soluble P-selectin a new marker of platelet activation? Atherosclerosis. 1997;128:135-138.
18. Andre P, Hartwell D, Hrachovinova I, Saffaripour S, Wagner DD. Pro-coagulant state resulting from high levels of P-selectin in blood. Proc Natl Acad Sci USA. 2000;97:13835-13840.
19. Blann AD, Fargher EB, McCollum CN. Increased soluble P-selecyn in ischaemic heart disease: A new marker for the progression of atherosclerosis. Blood Coagul Fibrinolys. 1997;8:383-390.
20. Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation. 2001; 103:491-495.
21. Hillis GS, Terregino C, Taggart P, Killian A, Zhao N, Dalsey WC. Elevated soluble P-selectin levels are associated with an increased risk of early adverse in patients with presumed myocardial infarction. Am Heart J. 2002;143:235-241.